PepZinGI® (Zinc-Carnosine for Gut Lining)

Evidence Level
Strong
2 Clinical Trials
3 Documented Benefits
4/5 Evidence Score

PepZinGI® (NutriScience Innovations) is a unique chelate of zinc and L-carnosine in a 1:1 molar ratio — creating a stable complex that selectively adheres to gastric and intestinal mucosal tissue, providing sustained zinc and carnosine release directly to the gut lining where it exerts its protective, healing, and anti-inflammatory effects. Unlike zinc supplements that transit quickly through the GI tract, PepZinGI® has a high affinity for the mucosal epithelium, enabling concentrated local action for leaky gut repair, heartburn relief, H. pylori inhibition, and gut barrier maintenance.

Studied Dose 75–150 mg/day PepZinGI® (polaprezinc); 75 mg twice daily for gut lining repair; established pharmaceutical drug in Japan at 150 mg/day for gastric ulcers; supplement dose lower
Active Compound Zinc-L-carnosine chelate (polaprezinc) — PepZinGI® by NutriScience Innovations; 75 mg PepZinGI® provides 16 mg zinc + 59 mg L-carnosine in stable chelate; approved pharmaceutical ingredient in Japan for gastric ulcers

Gut lining repair and leaky gut support

PepZinGI® adheres to gastric and intestinal mucosal epithelium and stimulates tight junction protein expression (claudin-1, occludin, ZO-1) — reducing intestinal permeability ('leaky gut'). Clinical studies confirm PepZinGI® significantly reduces intestinal permeability markers in athletes (who have elevated gut permeability from exercise stress) and in adults with gut barrier dysfunction. This gut barrier repair mechanism addresses the root cause of systemic inflammation from gut permeability.

Heartburn and gastric protection

As an approved pharmaceutical for gastric ulcers in Japan (under the name Polaprezinc/Z-103), zinc-carnosine demonstrates potent gastric mucosal protective effects — reducing acid-induced damage, promoting mucous layer thickening, stimulating mucosal cell proliferation, and inhibiting H. pylori adhesion to gastric epithelium. Clinical studies confirm significant reductions in heartburn, acid reflux symptoms, and gastric injury markers with PepZinGI® supplementation.

Anti-inflammatory gut protection

Carnosine and zinc from PepZinGI® inhibit NF-κB activation in intestinal epithelial cells — reducing pro-inflammatory cytokine production (IL-6, TNF-α) that drives gut inflammation. This anti-inflammatory mechanism complements the structural tight junction repair, providing both functional barrier protection and inflammatory resolution for comprehensive gut health support.

1

Mucosal adhesion with zinc and carnosine synergistic protection

The zinc-carnosine chelate in PepZinGI® has high affinity for mucous glycoproteins — binding directly to gastric and intestinal mucosal tissue rather than transiting through the GI tract. This mucosal adhesion provides sustained local release of zinc (which promotes epithelial cell proliferation and tight junction assembly) and carnosine (which scavenges reactive oxygen species, chelates metal ions that catalyze oxidative damage, and inhibits NF-κB inflammatory signaling). The synergistic action of both components — unavailable when zinc and carnosine are supplemented separately — explains PepZinGI®'s superior gut protection vs. zinc or carnosine alone.

1
PepZinGI® Intestinal Permeability in Athletes — Double-Blind RCT
PubMed

Randomized, double-blind, placebo-controlled crossover trial of PepZinGI® effects on exercise-induced intestinal permeability in trained athletes.

Trained athletes with elevated exercise-induced gut permeability. Crossover design.

PepZinGI® significantly reduced exercise-induced intestinal permeability markers (lactulose:mannitol ratio, zonulin) vs. placebo. Tight junction protein expression improved. GI symptoms reduced. Supports PepZinGI® for athlete gut health and general gut barrier repair applications.

2
Zinc-Carnosine (Polaprezinc) and Gastric Health — Japanese Pharmaceutical Studies
PubMed

Multiple clinical studies supporting Japan's pharmaceutical approval of polaprezinc (zinc-carnosine) for gastric ulcer treatment and H. pylori management.

Gastric ulcer patients and adults with gastric symptoms. Multiple clinical studies.

Polaprezinc (PepZinGI® equivalent) demonstrated significant gastric mucosal healing, H. pylori inhibition, and symptom relief in clinical studies leading to pharmaceutical approval in Japan. PepZinGI® provides these same active ingredients in supplement form for gut health applications.

Common Potential side effects

Generally very well tolerated — approved pharmaceutical in Japan with established safety record
Zinc content (16 mg per 75 mg dose) — monitor total daily zinc from all sources; UL is 40 mg/day
Mild GI effects possible — take with food

Important Drug interactions

Antibiotics (tetracyclines, quinolones) — zinc reduces absorption; separate by 2 hours
Penicillamine — zinc reduces drug absorption; avoid combination
Iron supplements — zinc and iron compete for absorption; take separately